NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta[TM]) for the treatment of relapsing-remitting multiple sclerosis (MS).
What does RR stand for?
RR stands for Relapsing-Remitting (Multiple Sclerosis)
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of RR
We have 90 other meanings of RR in our Acronym Attic
- Reference Reflector (Agilent)
- Refracted - Refracted
- Refugees de Rwanda
- Regierungsrat (Austria, Europe)
- Regional Reinforcement
- Register to Register Instruction
- Registered Representative
- Règlement des Radiocommunications (French: Radio Regulations; World Radiocommunication Conference; treaty)
- Rejection Report
Samples in periodicals archive:
In the first effort of its kind in MS, a team of investigators at seven medical centers has begun a two-year, controlled clinical trial of the hormone estriol added to standard therapy to treat MS in 130 women with relapsing-remitting MS.
There's some evidence that they may be beneficial for the relapsing-remitting form of MS.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources
Novartis' FTY720 is entering into phase III trials in relapsing-remitting MS and results may be available sometime in 2008.
MCT-175 for the treatment of relapsing-remitting MS.
For the first time, the Society recommended a treatment--the early use of one of three disease-modifying drugs then approved by the Food and Drug Administration (FDA) for relapsing-remitting MS.
Because it is the first drug capable of reducing the frequency of clinical exacerbations in ambulatory patients with relapsing-remitting MS, Med Ad News and FORTUNE magazine named Betaseron 1993's new product of the year.